Search

Your search keyword '"Sperr, P."' showing total 708 results
Start Over Author "Sperr, P."
708 results on '"Sperr, P."'

1. Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis: CHRONIC MYELOPROLIFERATIVE NEOPLASMS

Author

Rüfer, Axel, Nilius, Henning, Hermine, Olivier, Niedoszytko, Marek, Oude Elberink, Joanne N. G., Bonadonna, Patrizia, Shoumariyeh, Khalid, Gulen, Theo, Hartmann, Karin, Sabato, Vito, Angelova-Fischer, Irena, Baffoe, Daniel, Christen, Deborah, Belloni Fortina, Anna, Breynaert, Christine, Brockow, Knut, von Bubnoff, Nikolas, Bumbea, Horia, van Daele, Paul, Doubek, Michael, Dybedal, Ingunn, Elena, Chiara, Fokoloros, Christos, Górska, Aleksandra, Heizmann, Marc, Jentzsch, Madlen, Klein, Saskia, Lübke, Johannes, Mattsson, Mattias, Mulder, André, Panse, Jens, Schug, Tanja Daniela, Sciumè, Mariarita, Stefan, Alex, Sztormowska, Marlena, Várkonyi, Judit, Wortmann, Friederike, Yavuz, Akif Selim, Sperr, Martina, Gotlib, Jason, Reiter, Andreas, Triggiani, Massimo, Sperr, Wolfgang R., and Valent, Peter

Published
2025
Full Text
View/download PDF

3. 15 years Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO): achievements and future perspectives

Author

Valent, Peter, Hadzijusufovic, Emir, Sadovnik, Irina, Grunt, Thomas W., Peter, Barbara, Willmann, Michael, Herrmann, Harald, Ivanov, Daniel, Eisenwort, Gregor, Karlic, Heidrun, Greiner, Georg, Gleixner, Karoline V., Rülicke, Thomas, Dahlhoff, Maik, Staber, Philipp, Sperr, Wolfgang R., Pfeilstöcker, Michael, Lion, Thomas, Keil, Felix, and Hoermann, Gregor

Published
2024
Full Text
View/download PDF

4. Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study

Author

Lucini, Chantal, Obrová, Klára, Krickl, Isabella, Nogueira, Filomena, Kocmanová, Iva, Herndlhofer, Susanne, Gleixner, Karoline V., Sperr, Wolfgang R., Frank, Tijana, Andrade, Nuno, Peters, Christina, Engstler, Gernot, Dworzak, Michael, Attarbaschi, Andishe, van Grotel, Martine, van den Heuvel-Eibrink, Marry M., Moiseev, Ivan S, Rogacheva, Yuliya, Zubarovskaya, Ludmilla, Zubarovskaya, Natalia, Pichler, Herbert, Lawitschka, Anita, Koller, Elisabeth, Keil, Felix, Mayer, Jiří, Weinbergerová, Barbora, Valent, Peter, and Lion, Thomas

Published
2024
Full Text
View/download PDF

6. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS

Author

Bauer, Karin, Machherndl-Spandl, Sigrid, Kazianka, Lukas, Sadovnik, Irina, Gültekin, Sinan, Suessner, Susanne, Proell, Johannes, Lauf, Jeroen, Hoermann, Gregor, Eisenwort, Gregor, Häfner, Norman, Födermayr-Mayrleitner, Mathilde, Schmolke, Ann-Sofie, van der Kouwe, Emiel, Platzbecker, Uwe, Lion, Thomas, Weltermann, Ansgar, Zach, Otto, Webersinke, Gerald, Germing, Ulrich, Gabriel, Christian, Sperr, Wolfgang R., Béné, Marie C., Staber, Philipp B., Bettelheim, Peter, and Valent, Peter

Published
2023
Full Text
View/download PDF

8. Banana for scale: Gauging trends in academic interest by normalising publication rates to common and innocuous keywords

Author

Dalmaijer, Edwin S., Van Rheede, Joram, Sperr, Edwin V., and Tkotz, Juliane

Subjects
Computer Science - Digital Libraries, 92-00 (Primary), 92-04 (Secondary), J.3
Abstract

Many academics use yearly publication numbers to quantify academic interest for their research topic. While such visualisations are ubiquitous in grant applications, manuscript introductions, and review articles, they fail to account for the rapid growth in scientific publications. As a result, any search term will likely show an increase in supposed "academic interest". One proposed solution is to normalise yearly publication rates by field size, but this is arduous and difficult. Here, we propose an simpler index that normalises keywords of interest by a ubiquitous and innocuous keyword, such as "banana". Alternatively, one could opt for field-specific keywords or hierarchical structures (e.g. PubMed's Medical Subject Headings, MeSH) to compute "interest market share". Using this approach, we uncovered plausible trends in academic interest in examples from the medical literature. In neuroimaging, we found that not the supplementary motor area (as was previously claimed), but the prefrontal cortex is the most interesting part of the brain. In cancer research, we found a contemporary preference for cancers with high prevalence and clinical severity, and notable declines in interest for more treatable or likely benign neoplasms. Finally, we found that interest in respiratory viral infections spiked when strains showed potential for pandemic involvement, with SARS-CoV-2 and the COVID-19 pandemic being the most extreme example. In sum, the time is ripe for a quick and easy method to quantify trends in academic interest for anecdotal purposes. We provide such a method, along with software for researchers looking to implement it in their own writing., Comment: The software described in this manuscript can be found on https://github.com/esdalmaijer/bibliobanana

Published
2021

11. Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis

Author

Reiter, Andreas, Gotlib, Jason, Álvarez-Twose, Iván, Radia, Deepti H., Lübke, Johannes, Bobbili, Priyanka J., Wang, Aolin, Norregaard, Chelsea, Dimitrijevic, Saša, Sullivan, Erin, Louie-Gao, Melinda, Schwaab, Juliana, Galinsky, Ilene A., Perkins, Cecelia, Sperr, Wolfgang R., Sriskandarajah, Priya, Chin, Andi, Sendhil, Selvam R., Duh, Mei Sheng, Valent, Peter, and DeAngelo, Daniel J.

Published
2022
Full Text
View/download PDF

12. Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)

Author

Ustun, Celalettin, Morgan, Elizabeth, Moodie, Erica EM, Pullarkat, Sheeja, Yeung, Cecilia, Broesby‐Olsen, Sigurd, Ohgami, Robert, Kim, Young, Sperr, Wolfgang, Vestergaard, Hanne, Chen, Dong, Kluin, Philip M, Dolan, Michelle, Mrózek, Krzysztof, Czuchlewski, David, Horny, Hans‐Peter, George, Tracy I, Kristensen, Thomas Kielsgaard, Ku, Nam K, Yi, Cecilia Arana, Møller, Michael Boe, Marcucci, Guido, Baughn, Linda, Schiefer, Ana‐Iris, Hilberink, JR, Pullarkat, Vinod, Shanley, Ryan, Kohlschmidt, Jessica, Coulombe, Janie, Salhotra, Amandeep, Soma, Lori, Cho, Christina, Linden, Michael A, Akin, Cem, Gotlib, Jason, Hoermann, Gregor, Hornick, Jason, Nakamura, Ryo, Deeg, Joachim, Bloomfield, Clara D, Weisdorf, Daniel, Litzow, Mark R, Valent, Peter, Huls, Gerwin, Perales, Miguel‐Angel, and Borthakur, Gautam

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Pediatric Research Initiative, Rare Diseases, Pediatric Cancer, Clinical Research, Childhood Leukemia, Pediatric, Stem Cell Research - Nonembryonic - Human, Stem Cell Research, Genetics, Hematology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Core Binding Factors, Female, Humans, Leukemia, Myeloid, Acute, Male, Middle Aged, Risk Factors, Severity of Illness Index, Translocation, Genetic, Young Adult, acute myeloid leukemia, core-binding factor, disease-free survival, KIT mutation, predictive value, relapse, scoring system, Biochemistry and Cell Biology, Oncology and carcinogenesis
Abstract

BackgroundAlthough the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse.MethodsEleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22).ResultsComplete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P

Published
2018

13. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis

Author

Zanotti, Roberta, Bonifacio, Massimiliano, Lucchini, Giuseppe, Sperr, Wolfgang R., Scaffidi, Luigi, van Anrooij, Björn, Oude Elberink, Hanneke NC, Rossignol, Julien, Hermine, Olivier, Gorska, Aleksandra, Lange, Magdalena, Hadzijusufovic, Emir, Miething, Cornelius, Müller, Sabine, Perkins, Cecelia, Shomali, William, Elena, Chiara, Illerhaus, Anja, Jawhar, Mohamad, Parente, Roberta, Caroppo, Francesca, Solomianyi, Oleksii, Zink, Alexander, Mattsson, Mattias, Yavuz, Akif Selim, Panse, Jens, Varkonyi, Judit, Doubek, Michael, Sabato, Vito, Breynaert, Christine, Vucinic, Vladan, Schug, Tanja, Hägglund, Hans, Wortmann, Friederike, Brockow, Knut, Angelova-Fischer, Irena, Belloni Fortina, Anna, Triggiani, Massimo, Reiter, Andreas, Hartmann, Karin, Malcovati, Luca, Gotlib, Jason, Shoumariyeh, Khalid, Niedoszytko, Marek, Arock, Michel, Kluin-Nelemans, Hanneke C., Bonadonna, Patrizia, and Valent, Peter

Published
2022
Full Text
View/download PDF

17. A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting: R-EFECT study

Author

Petzer, Andreas L., Sperr, Wolfgang R., Buxhofer-Ausch, Veronika, Sliwa, Thamer, Schmidt, Stefan, Greil, Richard, Wölfler, Albert, Pichler, Petra, Dormann, Clemens, Burgstaller, Sonja, Tinchon, Christoph, Lang, Alois, Goebel, Florian, Uthman, Shanow, Muenchmeier, Niklas, and Valent, Peter

Published
2020
Full Text
View/download PDF

18. Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

Author

Kluin-Nelemans, Hanneke C., Reiter, Andreas, Illerhaus, Anja, van Anrooij, Bjorn, Hartmann, Karin, Span, Lambertus F. R., Gorska, Aleksandra, Niedoszytko, Marek, Lange, Magdalena, Scaffidi, Luigi, Zanotti, Roberta, Bonadonna, Patrizia, Perkins, Cecelia, Elena, Chiara, Malcovati, Luca, Shoumariyeh, Khalid, von Bubnoff, Nikolas, Parente, Roberta, Triggiani, Massimo, Schwaab, Juliana, Jawhar, Mohamad, Caroppo, Francesca, Fortina, Anna Belloni, Brockow, Knut, Zink, Alexander, Fuchs, David, Kilbertus, Alex, Yavuz, Akif Selim, Doubek, Michael, Mattsson, Mattias, Hagglund, Hans, Panse, Jens, Sabato, Vito, Aberer, Elisabeth, Niederwieser, Dietger, Breynaert, Christine, Várkonyi, Judit, Kennedy, Vanessa, Lortholary, Olivier, Jakob, Thilo, Hermine, Olivier, Rossignol, Julien, Arock, Michel, Gotlib, Jason, Valent, Peter, and Sperr, Wolfgang R.

Published
2020
Full Text
View/download PDF

19. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange

Author

Kühne, Lucas, Knöbl, Paul, Eller, Kathrin, Thaler, Johannes, Sperr, Wolfgang R., Gleixner, Karoline, Osterholt, Thomas, Kaufeld, Jessica, Menne, Jan, Buxhofer-Ausch, Veronika, Mühlfeld, Anja, Seelow, Evelyn, Schreiber, Adrian, Todorova, Polina, Cukoski, Sadrija, Jabs, Wolfram J., Özcan, Fedai, Gäckler, Anja, Schönfelder, Kristina, Seibert, Felix S., Westhoff, Timm, Schwenger, Vedat, Eichenauer, Dennis A., Völker, Linus A., Brinkkoetter, Paul T., Albert, Annemarie, Bramstedt, Jörn, Brand, Marcus, Brinkkötter, Paul T., Cukoski, Sadrija, Eichenauer, Dennis A., Elitok, Saban, Felten, Helmut, Gäckler, Anja, Geuther, Gesa, Harth, Ana, Hausberg, Martin, Hermann, Matthias, Hinkel, Ulrich P., Jabs, Wolfram Johannes, Kaufeld, Jessica, Klein, Gilles, Klemm, Kristin, Kolbrink, Benedikt, Kühne, Lucas, Menne, Jan, Miesbach, Wolfgang, Mühlfeld, Anja Susanne, Özcan, Fedai, Osterholt, Thomas, Pfrepper, Christian, Potthoff, Sebastian A., Radermacher, Jörg, Ruhe, Johannes, Schmidt, Tilman, Schönermarck, Ulf, Schönfelder, Kristina, Schreiber, Adrian, Schulte, Kevin, Schulte-Kemna, Lena, Schwenger, Vedat, Seelow, Evelyn, Seibert, Felix S., Todorova, Polina, Tölle - Charité, Markus, Völker, Linus A., Walendy, Victor, Wendt, Ralph, and Westhoff, Timm H.

Abstract

•Caplacizumab with immunosuppression, but without additional TPE, is an effective and safe treatment strategy for acute iTTP.

Published
2024
Full Text
View/download PDF

20. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

Author

Sirenko, Maria, Bernard, Elsa, Creignou, Maria, Domenico, Dylan, Farina, Andrea, Arango Ossa, Juan E., Kosmider, Olivier, Hasserjian, Robert, Jädersten, Martin, Germing, Ulrich, Sanz, Guillermo, van de Loosdrecht, Arjan A., Gurnari, Carmelo, Follo, Matilde Yung, Thol, Felicitas, Zamora, Lurdes, Pinheiro, Ronald Feitosa, Pellagatti, Andrea, Elias, Harold K., Haase, Detlef, Sander, Birgitta, Orna, Elisa, Zoldan, Katharina, Eder, Lea Naomi, Sperr, Wolfgang R., Thalhammer, Renate, Ganster, Christina, Adès, Lionel, Tobiasson, Magnus, Palomo, Laura, Della Porta, Matteo Giovanni, Huberman, Kety, Fenaux, Pierre, Belickova, Monika, Savona, Michael R., Klimek, Virginia M., Santos, Fabio P. S., Boultwood, Jacqueline, Kotsianidis, Ioannis, Santini, Valeria, Solé, Francesc, Platzbecker, Uwe, Heuser, Michael, Valent, Peter, Finelli, Carlo, Voso, Maria Teresa, Shih, Lee-Yung, Ogawa, Seishi, Fontenay, Michaela, Jansen, Joop H., Cervera, Jose, Ebert, Benjamin L., Bejar, Rafael, Greenberg, Peter L., Gattermann, Norbert, Malcovati, Luca, Cazzola, Mario, Beck, David B., Hellström-Lindberg, Eva, and Papaemmanuil, Elli

Abstract

•UBA1mutations were identified in 1% of patients with MDS and 7% of patients lacking myeloid mutations or established disease classification.•Inflammatory clinical presentation and vacuoles were observed in 83% and 71%, respectively, of patients with pathogenic UBA1mutations.

Published
2024
Full Text
View/download PDF

22. The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML): A representative and useful real-life data source for further biomedical research

Author

Geissler, Klaus, Jäger, Eva, Barna, Agnes, Gurbisz, Michael, Marschon, Renate, Graf, Temeida, Graf, Elmir, Borjan, Bojana, Jilch, Ruth, Geissler, Christoph, Hoermann, Gregor, Esterbauer, Harald, Schwarzinger, Ilse, Nösslinger, Thomas, Pfeilstöcker, Michael, Tüchler, Heinz, Reisner, Regina, Sliwa, Thamer, Keil, Felix, Bettelheim, Peter, Machherndl-Spandl, Sigrid, Doleschal, Bernhard, Zach, Otto, Weltermann, Ansgar, Heibl, Sonja, Thaler, Josef, Zebisch, Armin, Sill, Heinz, Stauder, Reinhard, Webersinke, Gerald, Petzer, Andreas, Kusec, Rajko, Ulsperger, Ernst, Schneeweiss, Bruno, Berger, Jörg, Öhler, Leopold, Germing, Ulrich, Sperr, Wolfgang R., Knöbl, Paul, Jäger, Ulrich, and Valent, Peter

Published
2019
Full Text
View/download PDF

23. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis

Author

Jawhar, Mohamad, Döhner, Konstanze, Kreil, Sebastian, Schwaab, Juliana, Shoumariyeh, Khalid, Meggendorfer, Manja, Span, Lambert L. F., Fuhrmann, Stephan, Naumann, Nicole, Horny, Hans-Peter, Sotlar, Karl, Kubuschok, Boris, von Bubnoff, Nikolas, Spiekermann, Karsten, Heuser, Michael, Metzgeroth, Georgia, Fabarius, Alice, Klein, Stefan, Hofmann, Wolf-Karsten, Kluin-Nelemans, Hanneke C., Haferlach, Torsten, Döhner, Hartmut, Cross, Nicholas C. P., Sperr, Wolfgang R., Valent, Peter, and Reiter, Andreas

Published
2019
Full Text
View/download PDF

24. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM

Author

Lübke, Johannes, Schmid, Alicia, Christen, Deborah, Oude Elberink, Hanneke N. G., Span, Lambert F. R., Niedoszytko, Marek, Gorska, Aleksandra, Lange, Magdalena, Gleixner, Karoline V., Hadzijusufovic, Emir, Stefan, Alex, Angelova-Fischer, Irena, Zanotti, Roberta, Bonifacio, Massimiliano, Bonadonna, Patrizia, Shoumariyeh, Khalid, von Bubnoff, Nikolas, Müller, Sabine, Perkins, Cecelia, Elena, Chiara, Malcovati, Luca, Hagglund, Hans, Mattsson, Mattias, Parente, Roberta, Varkonyi, Judit, Fortina, Anna Belloni, Caroppo, Francesca, Brockow, Knut, Zink, Alexander, Breynaert, Christine, Leven, Toon, Yavuz, Akif Selim, Doubek, Michael, Sabato, Vito, Schug, Tanja, Hartmann, Karin, Triggiani, Massimo, Gotlib, Jason, Hermine, Olivier, Arock, Michel, Kluin-Nelemans, Hanneke C., Panse, Jens, Sperr, Wolfgang R., Valent, Peter, Reiter, Andreas, and Schwaab, Juliana

Abstract

•Serum chemistry profiling is of diagnostic and prognostic relevance based on easily accessible parameters.•Serum chemistry markers help to assess and quantify organ damage.

Published
2024
Full Text
View/download PDF

25. Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives

Author

Valent, Peter, Hadzijusufovic, Emir, Grunt, Thomas, Karlic, Heidrun, Peter, Barbara, Herrmann, Harald, Eisenwort, Gregor, Hoermann, Gregor, Schulenburg, Axel, Willmann, Michael, Hubmann, Rainer, Shehata, Medhat, Selzer, Edgar, Gleixner, Karoline V., Rülicke, Thomas, Sperr, Wolfgang R., Marian, Brigitte, Pfeilstöcker, Michael, Pehamberger, Hubert, Keil, Felix, Jäger, Ulrich, and Zielinski, Christoph

Published
2018
Full Text
View/download PDF

26. Tumor necrosis factor α promotes clonal dominance of KITD816V+cells in mastocytosis: role of survivin and impact on prognosis

Author

Greiner, Georg, Witzeneder, Nadine, Klein, Klara, Tangermann, Simone, Kodajova, Petra, Jaeger, Eva, Ratzinger, Franz, Gerner, Marlene C., Jawhar, Mohamad, Baumgartner, Sigrid, Fruehwirth, Karin, Schmetterer, Klaus G., Zuber, Johannes, Gleixner, Karoline V., Mayerhofer, Matthias, Schwarzinger, Ilse, Simonitsch-Klupp, Ingrid, Esterbauer, Harald, Baer, Constance, Walter, Wencke, Meggendorfer, Manja, Strassl, Robert, Haferlach, Torsten, Hartmann, Karin, Kenner, Lukas, Sperr, Wolfgang R., Reiter, Andreas, Sexl, Veronika, Arock, Michel, Valent, Peter, and Hoermann, Gregor

Abstract

•KITD816V confers resistance to TNF via BIRC5 (survivin) and promotes clonal dominance.•High TNF levels are associated with inferior survival in SM.

Published
2024
Full Text
View/download PDF

27. Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemia

Author

Huemer, Florian, Weiss, Lukas, Faber, Viktoria, Neureiter, Daniel, Egle, Alexander, Geissler, Klaus, Voskova, Daniela, Zebisch, Armin, Burgstaller, Sonja, Pichler, Angelika, Stauder, Reinhard, Sperr, Wolfgang, Lang, Alois, Pfeilstöcker, Michael, Machherndl-Spandl, Sigrid, Stampfl, Margarete, Greil, Richard, and Pleyer, Lisa

Published
2018
Full Text
View/download PDF

31. Service Restoration in the Medium Voltage Grid Minimizing the SAIDI Contribution After Primary Substation Failures

Author

Sperr, Felix, Stai, Eleni, Venkatraman, Ashwin, Krause, Thilo, and Hug, Gabriela

Abstract

One of the most widely used reliability measures for the electric grid is the System Average Interruption Duration Index (SAIDI), i.e. how many minutes the average customer is without power per year. Primary substation failures may significantly increase SAIDI, since they affect a large number of customers. This may be avoided by improving the service restoration process, which requires solving complex non-convex combinatorial problems. Hence, this paper proposes an algorithm for smart, SAIDI-optimizing service restoration in meshed MV grids after primary substation failures. We first formulate service restoration as a Mixed-Integer Linear Programming (MILP) problem by using a linearization of the power flow equations that is proper for meshed grids and by applying exact Big M relaxations for linearizing other involved non-convexities. The decisions include among others the travel routes of the field crew and account for the grid security constraints. Then, we propose a low complexity heuristic iterative method that optimally solves the MILP problem. The results for a test case in Switzerland suggest that the SAIDI contribution can be reduced by more than 10% compared to the currently deployed restoration strategy at the utility. Also, they show the effectiveness of the SAIDI objective versus common objectives in the literature.

Published
2024
Full Text
View/download PDF

38. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)

Author

Della Porta, M G, Tuechler, H, Malcovati, L, Schanz, J, Sanz, G, Garcia-Manero, G, Solé, F, Bennett, J M, Bowen, D, Fenaux, P, Dreyfus, F, Kantarjian, H, Kuendgen, A, Levis, A, Cermak, J, Fonatsch, C, Le Beau, M M, Slovak, M L, Krieger, O, Luebbert, M, Maciejewski, J, Magalhaes, S M M, Miyazaki, Y, Pfeilstöcker, M, Sekeres, M A, Sperr, W R, Stauder, R, Tauro, S, Valent, P, Vallespi, T, van de Loosdrecht, A A, Germing, U, Haase, D, Greenberg, P L, and Cazzola, M

Published
2015
Full Text
View/download PDF

41. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT

Author

Valent, Peter, Hoermann, Gregor, Bonadonna, Patrizia, Hartmann, Karin, Sperr, Wolfgang R., Broesby-Olsen, Sigurd, Brockow, Knut, Niedoszytko, Marek, Hermine, Olivier, Chantran, Yannick, Butterfield, Joseph H., Greiner, Georg, Carter, Melody C., Sabato, Vito, Radia, Deepti H., Siebenhaar, Frank, Triggiani, Massimo, Gülen, Theo, Alvarez-Twose, Ivan, Staudinger, Thomas, Traby, Ludwig, Sotlar, Karl, Reiter, Andreas, Horny, Hans-Peter, Orfao, Alberto, Galli, Stephen J., Schwartz, Lawrence B., Lyons, Jonathan J., Gotlib, Jason, Metcalfe, Dean D., Arock, Michel, and Akin, Cem

Abstract

Physiological levels of basal serum tryptase vary among healthy individuals, depending on the numbers of mast cells, basal secretion rate, copy numbers of the TPSAB1gene encoding alpha tryptase, and renal function. Recently, there has been a growing debate about the normal range of tryptase because individuals with the hereditary alpha tryptasemia (HαT) trait may or may not be symptomatic, and if symptomatic, uncertainty exists as to whether this trait directly causes clinical phenotypes or aggravates certain conditions. In fact, most HαT-positive cases are regarded as asymptomatic concerning mast cell activation. To address this point, experts of the European Competence Network on Mastocytosis (ECNM) and the American Initiative in Mast Cell Diseases met at the 2022 Annual ECNM meeting and discussed the physiological tryptase range. Based on this discussion, our faculty concluded that the normal serum tryptase range should be defined in asymptomatic controls, inclusive of individuals with HαT, and based on 2 SDs covering the 95% confidence interval. By applying this definition in a literature screen, the normal basal tryptase in asymptomatic controls (HαT-positive persons included) ranges between 1 and 15 ng/mL. This definition should avoid overinterpretation, unnecessary referrals, and unnecessary anxiety or anticipatory fear of illness in healthy individuals.

Published
2023
Full Text
View/download PDF

43. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Author

Pleyer, Lisa, Burgstaller, Sonja, Girschikofsky, Michael, Linkesch, Werner, Stauder, Reinhard, Pfeilstocker, Michael, Schreder, Martin, Tinchon, Christoph, Sliwa, Thamer, Lang, Alois, Sperr, Wolfgang R., Krippl, Peter, Geissler, Dietmar, Voskova, Daniela, Schlick, Konstantin, Thaler, Josef, Machherndl-Spandl, Sigrid, Theiler, Georg, Eckmüllner, Otto, and Greil, Richard

Published
2014
Full Text
View/download PDF

44. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit

Author

Wohlfarth, Philipp, Staudinger, Thomas, Sperr, Wolfgang R., Bojic, Andja, Robak, Oliver, Hermann, Alexander, Laczika, Klaus, Carlström, Alexander, Riss, Katharina, Rabitsch, Werner, Bojic, Marija, Knoebl, Paul, Locker, Gottfried J., Obiditsch, Maria, Fuhrmann, Valentin, Schellongowski, Peter, and Arbeitsgruppe für hämato-onkologische Intensivmedizin der Österreichischen Gesellschaft für Internistische und Allgemeine Intensivmedizin und Notfallmedizin (ÖGIAIN)

Published
2014
Full Text
View/download PDF

49. European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives

Author

Valent, Peter, Arock, Michel, Bonadonna, Patrizia, Brockow, Knut, Broesby-Olsen, Sigurd, Escribano, Luis, Gleixner, Karoline V., Grattan, Clive, Hadzijusufovic, Emir, Hägglund, Hans, Hermine, Olivier, Horny, Hans-Peter, Kluin-Nelemans, Hanneke C., Maurer, Marcus, Niedoszytko, Marek, Nedoszytko, Boguslaw, Nilsson, Gunnar, Oude-Elberink, Hanneke N. G., Orfao, Alberto, Radia, Deepti, Reiter, Andreas, Siebenhaar, Frank, Sotlar, Karl, Sperr, Wolfgang R., Triggiani, Massimo, VanDoormaal, Jaap J., Várkonyi, Judit, Yavuz, Selim, and Hartmann, Karin

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results